You are here: Home » Companies » News
Business Standard

Zydus Cadila to enter $68-mn market after US FDA nod for breast cancer drug

Zydus Cadila has more than 220 approvals and so far

Press Trust of India  |  New Delhi 

breast cancer
Photo: Shutterstock

Drug firm Friday said it has received final approval from the US health regulator to market Exemestane tablets, used for the treatment of

The company has received approval from the (USFDA) to market the drug in the strength of 25 mg, said in a BSE filing.

The company said it will manufacture the drug at the group's formulations manufacturing facility at SEZ, Ahmedabad.

Quoting IMS Health data for August 2018, the company said the estimated sale for Exemestane tablets is $68.6 million.

has more than 220 approvals and so far filed over 330 abbreviated new drug applications (ANDAs).

Shares of the company's listed entity were trading 0.13 per cent higher at Rs 383.20 apiece on the BSE.

First Published: Fri, October 05 2018. 12:50 IST